OBJECTIVE: To estimate a new technique for quantifying regional lung motion using 3D-MRI in healthy volunteers and to apply the technique in patients with intra- or extrapulmonary tumors. MATERIALS AND METHODS: Intraparenchymal lung motion during a whole breathing cycle was quantified in 30 healthy volunteers using 3D-dynamic MRI (FLASH [fast low angle shot] 3D, TRICKS [time-resolved interpolated contrast kinetics]). Qualitative and quantitative vector color maps and cumulative histograms were performed using an introduced semiautomatic algorithm. An analysis of lung motion was performed and correlated with an established 2D-MRI technique for verification. As a proof of concept, the technique was applied in five patients with non-small cell lung cancer (NSCLC) and 5 patients with malignant pleural mesothelioma (MPM). RESULTS: The correlation between intraparenchymal lung motion of the basal lung parts and the 2D-MRI technique was significant (r = 0.89, p < 0.05). Also, the vector color maps quantitatively illustrated regional lung motion in all healthy volunteers. No differences were observed between both hemithoraces, which was verified by cumulative histograms. The patients with NSCLC showed a local lack of lung motion in the area of the tumor. In the patients with MPM, there was global diminished motion of the tumor bearing hemithorax, which improved significantly after chemotherapy (CHT) (assessed by the 2D- and 3D-techniques) (p < 0.01). Using global spirometry, an improvement could also be shown (vital capacity 2.9 +/- 0.5 versus 3.4 L +/- 0.6, FEV1 0.9 +/- 0.2 versus 1.4 +/- 0.2 L) after CHT, but this improvement was not significant. CONCLUSION: A 3D-dynamic MRI is able to quantify intraparenchymal lung motion. Local and global parenchymal pathologies can be precisely located and might be a new tool used to quantify even slight changes in lung motion (e.g. in therapy monitoring, follow-up studies or even benign lung diseases).
OBJECTIVE: To estimate a new technique for quantifying regional lung motion using 3D-MRI in healthy volunteers and to apply the technique in patients with intra- or extrapulmonary tumors. MATERIALS AND METHODS: Intraparenchymal lung motion during a whole breathing cycle was quantified in 30 healthy volunteers using 3D-dynamic MRI (FLASH [fast low angle shot] 3D, TRICKS [time-resolved interpolated contrast kinetics]). Qualitative and quantitative vector color maps and cumulative histograms were performed using an introduced semiautomatic algorithm. An analysis of lung motion was performed and correlated with an established 2D-MRI technique for verification. As a proof of concept, the technique was applied in five patients with non-small cell lung cancer (NSCLC) and 5 patients with malignant pleural mesothelioma (MPM). RESULTS: The correlation between intraparenchymal lung motion of the basal lung parts and the 2D-MRI technique was significant (r = 0.89, p < 0.05). Also, the vector color maps quantitatively illustrated regional lung motion in all healthy volunteers. No differences were observed between both hemithoraces, which was verified by cumulative histograms. The patients with NSCLC showed a local lack of lung motion in the area of the tumor. In the patients with MPM, there was global diminished motion of the tumor bearing hemithorax, which improved significantly after chemotherapy (CHT) (assessed by the 2D- and 3D-techniques) (p < 0.01). Using global spirometry, an improvement could also be shown (vital capacity 2.9 +/- 0.5 versus 3.4 L +/- 0.6, FEV1 0.9 +/- 0.2 versus 1.4 +/- 0.2 L) after CHT, but this improvement was not significant. CONCLUSION: A 3D-dynamic MRI is able to quantify intraparenchymal lung motion. Local and global parenchymal pathologies can be precisely located and might be a new tool used to quantify even slight changes in lung motion (e.g. in therapy monitoring, follow-up studies or even benign lung diseases).
Authors: Christian Plathow; Sebastian Ley; Christian Fink; Michael Puderbach; Waldemar Hosch; Astrid Schmähl; Jürgen Debus; Hans-Ulrich Kauczor Journal: Int J Radiat Oncol Biol Phys Date: 2004-07-15 Impact factor: 7.038
Authors: Christian Plathow; Sebastian Ley; Christian Fink; Michael Puderbach; Melanie Heilmann; Ivan Zuna; Hans-Ulrich Kauczor Journal: Invest Radiol Date: 2004-04 Impact factor: 6.016
Authors: Holger Hof; Klaus K Herfarth; Marc Münter; Angelika Hoess; Johann Motsch; Michael Wannenmacher; Jürgen Debus J Journal: Int J Radiat Oncol Biol Phys Date: 2003-06-01 Impact factor: 7.038
Authors: Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti Journal: J Clin Oncol Date: 2003-07-15 Impact factor: 44.544
Authors: Holger Hof; Klaus K Herfarth; Marc Münter; Marco Essig; Michael Wannenmacher; Jürgen Debus Journal: Strahlenther Onkol Date: 2003-08 Impact factor: 3.621
Authors: Vincent M Remouchamps; Nicola Letts; Di Yan; Frank A Vicini; Michel Moreau; Julie A Zielinski; Jian Liang; Larry L Kestin; Alvaro A Martinez; John W Wong Journal: Int J Radiat Oncol Biol Phys Date: 2003-11-15 Impact factor: 7.038
Authors: Christian Plathow; Christian Fink; Sebastian Ley; Michael Puderbach; Monica Eichinger; Astrid Schmähl; Hans-Ulrich Kauczor Journal: Eur Radiol Date: 2004-05-01 Impact factor: 5.315
Authors: Katja Mogalle; Adria Perez-Rovira; Pierluigi Ciet; Stephan C A Wens; Pieter A van Doorn; Harm A W M Tiddens; Ans T van der Ploeg; Marleen de Bruijne Journal: PLoS One Date: 2016-07-08 Impact factor: 3.240